Harbin Pharmaceutical Group Co., Ltd., commonly referred to as Harbin Pharma, is a leading player in the pharmaceutical industry, headquartered in Harbin, China. Established in 1997, the company has made significant strides in the development and production of a wide range of pharmaceutical products, including traditional Chinese medicine, chemical drugs, and biopharmaceuticals. With a strong presence in both domestic and international markets, Harbin Pharma is renowned for its commitment to innovation and quality. The company’s core offerings include prescription medications, over-the-counter products, and health supplements, distinguished by their efficacy and adherence to stringent safety standards. Recognised for its robust research and development capabilities, Harbin Pharmaceutical Group has achieved notable milestones, positioning itself as a trusted name in healthcare. Its dedication to advancing medical solutions continues to enhance its reputation within the global pharmaceutical landscape.
How does Harbin Pharmaceutical Group Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Harbin Pharmaceutical Group Co., Ltd.'s score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Harbin Pharmaceutical Group Co., Ltd., headquartered in China (CN), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, Harbin Pharmaceutical Group has not cascaded any emissions data from a parent or related organization, nor does it appear to have established any formal commitments to reduce its carbon footprint. This lack of publicly available information suggests that the company may still be in the early stages of developing its climate strategy or reporting framework. In the context of the pharmaceutical industry, companies are increasingly expected to adopt robust climate commitments and transparent reporting practices. As such, Harbin Pharmaceutical Group may benefit from aligning with industry standards and setting measurable targets to enhance its sustainability profile.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Harbin Pharmaceutical Group Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.